Avidity
Michael Bird's work experience begins with their current position as a Scientist 1 at Avidity Biosciences, Inc. Michael started in May 2022 and is still employed there.
Prior to that, they worked at Scripps Research as a PHD Candidate from August 2016 to April 2022.
Before their time at Scripps Research, Michael was involved in research as an Undergraduate Researcher at Tufts University from October 2013 to May 2016. During this time, they also worked as an On Call Tutor from September 2013 to May 2016.
Michael Bird completed their education with a Bachelor's Degree in Biochemistry and Applied Mathematics from Tufts University, where they studied from 2012 to 2016. Michael later pursued a Doctor of Philosophy (Ph.D.) in Chemistry from Scripps Research, starting in 2016 and completing it in 2022. Additionally, they obtained a certification in Project Management Simplified from LinkedIn in April 2023.
This person is not in the org chart
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.